Capricor Therapeutics is trading at $6.22, up 5.78%, with no clear company-specific catalyst identified for the gain on October 22.
- Its investor news page lists an October 5 update as its latest press release.
- The FDA’s Deramiocel decision is expected by November 22; recent coverage describes continued investor uncertainty around approval.
- The broader market is lower. Trading volume and other activity details are unavailable.